7 Jul 2020 15:48
7 July 2020
Correction: PDMR Shareholding
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, provides an amendment to the PDMR Shareholding announcement, released on 5 June 2020, as follows:
Section 4d of the announcement (price per share), and Section 4e (price) have been corrected to 886.5p. All other details remain the same.
The full amended text is shown below.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | John Hartup | |
2 | Reason for the notification | ||
a) | Position/status | Non-Executive Director | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Clinigen Group plc | |
b) | Legal Entity Identifier | 213800OBIKGI2JYYS227 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
GB00B89J2419 | |
b) | Nature of the transaction | Sale of shares | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
886.5p per share | 5,000 shares | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
5,000 shares 886.5p £44,325 | |
f) | Date of the transaction | 5 June 2020 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
Contact details
Clinigen Group plc | Tel: +44 (0) 1283 495010 |
Shaun Chilton, Chief Executive Officer Nick Keher, Chief Financial Officer Matt Parrish, Head of Investor Relations |
|
|
|
J.P.Morgan Cazenove - Nominated Adviser & Joint Broker | Tel: +44 (0) 20 7742 4000 |
James Mitford / Hemant Kapoor |
|
|
|
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas |
|
|
|
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Phillip Marriage | Email: clinigen@instinctif.com |
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com.